Content about Insulin therapy

April 3, 2014

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes. 

January 21, 2014

Novo Nordisk has launched a new insulin pen designed for children with diabetes.

NEW YORK — Novo Nordisk has launched a new insulin pen designed for children with diabetes.

The new NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function, the company said.

August 21, 2013

The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

PLAINSBORO, N.J. — The Food and Drug Administration has given the green light to an insulin pen made by Novo Nordisk for half-unit dosing, the drug maker said Wednesday.

November 9, 2012

A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

Novo Nordisk said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.

June 12, 2012

One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.

PHILADELPHIA — One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.

June 11, 2012

An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.

PHILADELPHIA — An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.

May 22, 2012

The Food and Drug Administration has approved a treatment for Type 1 diabetes in children ages 2 to 5 years.

PRINCETON, N.J. — The Food and Drug Administration has approved a treatment for Type 1 diabetes in children ages 2 to 5 years.

Drug maker Novo Nordisk announced Tuesday the additional approval of Levemir (insulin detemir [rDNA origin]). The insulin already was approved for Type 1 diabetes in older children and adults and Type 2 diabetes in adults, and the drug maker said the new FDA approval made Levemir the only basal insulin analog for use in the 2 to 5 year age group.

April 9, 2012

The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.

PRINCETON, N.J. — The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.

February 1, 2012

Self-monitoring blood glucose levels in Type 2 diabetics not on an insulin regimen may contribute little to managing the disease, according to an analysis published online last month by The Cochran Library.

CHICHESTER, England — Self-monitoring blood glucose levels in Type 2 diabetics not on an insulin regimen may contribute little to managing the disease, according to an analysis published online last month by The Cochran Library.

December 1, 2011

Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.

INDIANAPOLIS — Many people with Type 2 diabetes have managed to integrate the treatments they must take into their daily lives, but many do not reach their blood-glucose goals after they start insulin therapy.

Drug maker Eli Lilly is partnering with Brigham and Women's Hospital in Boston in a study that started in July and has enrolled 4,500 people in 17 countries to find out why many people with the disease resist a progression of insulin therapy.

November 16, 2011

The Food and Drug Administration has approved a new insulin-delivery system for Type 1 diabetes made by Tandem Diabetes Care, the company said Wednesday.

SAN DIEGO — The Food and Drug Administration has approved a new insulin-delivery system for Type 1 diabetes made by Tandem Diabetes Care, the company said Wednesday.

Tandem announced the approval of the T:slim, a pump that the company said is the first to have a color touch screen and is the smallest insulin pump system available, in addition to being one of the first to be approved under the FDA's new Infusion Pump Improvement initiative.

September 16, 2011

A diabetes drug made by Bristol-Myers Squibb and AstraZeneca significantly reduced Type 2 diabetes patients' blood-sugar levels, compared with placebo, when added to insulin, according to results of a new study.

PRINCETON, N.J. — A diabetes drug made by Bristol-Myers Squibb and AstraZeneca significantly reduced Type 2 diabetes patients' blood-sugar levels, compared with placebo, when added to insulin, according to results of a new study.

The two companies presented results of a 24-week extension to a 52-week study of Onglyza (saxagliptin) at the European Association for the Study of Diabetes' 47th annual meeting in Lisbon, Portugal; they had presented results from the original study at the American Diabetes Association's scientific sessions in San Diego in June.

September 13, 2011

An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

PARIS — An insulin analogue made by Sanofi appears to work better in certain cases than competing treatments at reducing weight gain and controlling blood sugar among patients with Type 2 diabetes.

July 6, 2011

Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

June 27, 2011

Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

SAN DIEGO — Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.

The drug maker found that combining Victoza (liraglutide [rDNA origin] injection) with metformin and/or sulfonylurea helped patients achieve blood-sugar control.

June 17, 2011

A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

BUFFALO, N.Y. — A popular Type 2 diabetes treatment may help Type 1 diabetics achieve control of their blood-glucose levels, according to a small, observational study conducted at the University of Buffalo.

June 9, 2011

Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

INDIANAPOLIS — Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.

May 13, 2011

Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.

NEW YORK — Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.

Researchers said they monitored the sleep of 40 subjects with diabetes for a duration of six nights and also measured the subjects' insulin and glucose levels during clinical examinations. The subjects also reported if they generally suffered from symptoms of such sleep disturbances as insomnia, snoring or sleep apnea.

March 28, 2011

A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

NEW YORK — A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.

March 14, 2011

A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

DANBURY, Conn. — A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.

Biodel said BIOD-105 and BIOD-107, known as ultra rapid-acting insulins, are designed to result in more rapid insulin action, compared with currently marketed mealtime insulin analogs.

December 13, 2010

In patients with Type 1 diabetes, the islet cells of the pancreas are destroyed, thus eliminating the organ’s ability to produce insulin.

NEW YORK — In patients with Type 1 diabetes, the islet cells of the pancreas are destroyed, thus eliminating the organ’s ability to produce insulin.

But researchers at Georgetown University have found a way to recreate them using cells from the testicles, according to published reports.

WebMD reported that the researchers took the testicular tissue, extracted the stem cells and used them to create new islet cells. Injecting them into the pancreases of mice with diabetes. The researchers found that the cells began to secrete insulin.

November 2, 2010

The Food and Drug Administration has turned down an application for an insulin product made...

DANBURY, Conn. The Food and Drug Administration has turned down an application for an insulin product made by Biodel, Biodel said.

 

The drug maker announced that it received a complete response letter from the FDA for Linjeta (human insulin [rDNA origin]) for the treatment of Type 1 and Type 2 diabetes.

 

 

November 2, 2010

The CEO of drug maker Eli Lilly has called for a “wave of invention” to...

CLEVELAND The CEO of drug maker Eli Lilly has called for a “wave of invention” to combat diabetes.

Speaking at the Cleveland Clinic Medical Innovation Summit, John Lechleiter said breakthroughs against the disease are needed as urgently today as a century ago, noting that the disease could create a “health and economic time bomb,” as 1-in-3 Americans are forecasted to have the disease by 2050.

 

September 14, 2010

Oramed Pharmaceuticals has seen promising results from a clinical trial of an oral insulin for...

JERUSALEM Oramed Pharmaceuticals has seen promising results from a clinical trial of an oral insulin for diabetes, the Israeli drug maker said.

 

The company said its exploratory clinical trial of the oral insulin capsule ORMD-0801 was successful. The company is developing the capsule as a treatment for patients with uncontrolled Type 1 diabetes. The company also is developing the oral insulin as a treatment for Type 2 diabetes.

 

 

August 8, 2010

A company that develops healthcare and information management products has applied for a patent for...

DELRAY BEACH, Fla. A company that develops healthcare and information management products has applied for a patent for an insulin-pen tracking and recording device.